Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologySkin TumorsTrial Update

Study on Growth of Skin Neurofibromas in Neurofibromatosis Type 1 Initiated by NCI

The National Cancer Institute is conducting a study to investigate the growth patterns of dermal neurofibromas in patients with neurofibromatosis type 1.

Published: June 19, 2026
Updated: June 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Skin Tumors
Asset: Study
Indication: National Cancer Institute
Trial SummaryCLN

Phase III

National Cancer Institute

Status

Initiated

Signal Score

6.8

Signal assessment

Signal strength

moderate

Confidence level

moderate

Signalmoderate
Confidencemoderate

Why it matters

This study by the National Cancer Institute is crucial as it may uncover significant insights into the growth patterns of dermal neurofibromas, which could inform future therapeutic strategies for neurofibromatosis type 1. Pharma strategy teams should closely monitor the outcomes, as they could influence the development of targeted therapies in this area.

Recommended action

Humanexa recommends Monitor.

Analysis

Key milestones include interim results on tumor growth rates and genetic findings over the 24-month follow-up period.

Related companies & assets

Assets

  • Study →

Sources & Humanexa intelligence

Source links

  • Study on Growth of Skin Neurofibromas in Neurofibromatosis Type 1 Initiated by NCI ↗

Related Humanexa pages

  • Study on Growth of Skin Neurofibromas in Neurofibromatosis Type 1 Initiated by NCI →

Related signals

Trial SummaryCLN

Phase III

Oncology / Multiple Myeloma

Status

Active

Signal Score

8.4

Clinicalhigh signal

Selinexor shows promise in high-risk multiple myeloma with XVRd regimen

The study evaluates the efficacy and safety of the XVRd regimen in newly diagnosed multiple myeloma patients with high-risk factors.

August 5, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / Glioma

Status

Active

Signal Score

8.4

Clinicalhigh signal

Management of BRAF Inhibitors in Glioma: Addressing Toxicity and Resistance

BRAF inhibitors are effective for BRAF-altered gliomas, but resistance and toxicity management are critical challenges.

August 5, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

  1. Home
  2. /Clinical
  3. /Study on Growth of Skin Neurofibromas in Neurofibromatosis Type 1 Initiated by NCI